Pfizer targets VEGF bispecific white space
The company diverges from Summit and Bristol/BioNTech with a pivotal endometrial trial.
MacroGenics changes its tune on Linnet
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
Another solstice for CTLA-4
Solstice Oncology acquires porustobart from Harbour Biomed.
The relentless march of VEGF bispecifics
Two new pivotal Chinese first-line trials have started in lung cancer.
